Biomarkers, prediction, and prognosis in non-small-cell lung cancer: A platform for personalized treatment

Clinical Lung Cancer

Volumn 12, Issue 6, 2011, Pages 360-368

  Sudhindra, Akshay ^a   Ochoa, Roberto ^a   Santos, Edgardo S ^a  

^a UNIVERSITY OF MIAMI   (United States)

Author keywords

tubulin; BRCA 1; EML4 ALK; Epidermal growth factor receptor (EGFR); Excision repair cross complementing enzyme 1 (ERCC1); Ribonucleotide reductase M 1 protein (RRM1); Thymidilate synthase (TS)

Indexed keywords

BIOLOGICAL MARKER; PLATINUM DERIVATIVE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER SURVIVAL; GENE MUTATION; HUMAN; LUNG NON SMALL CELL CANCER; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PREDICTION; PROGNOSIS; TREATMENT RESPONSE;

BIOLOGICAL MARKERS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; INDIVIDUALIZED MEDICINE; LUNG NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS;

EID: 80155190075     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2011.02.003     Document Type: Article

References (84)

1. A. Jemal, R. Siegel, and E. Ward Cancer statistics 2009 CA Cancer J Clin 59 4 2009 225 249
2. J.H. Schiller, D. Harrington, and C.P. Belani Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer N Engl J Med 346 2002 92 98 (Pubitemid 34438899)
3. A. Sandler, R. Gray, and M.C. Perry Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 24 2006 2542 2550 (Pubitemid 44917502)
4. R. Pirker, J.R. Pereira, and A. Szczesna Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial Lancet 373 9674 2009 1525 1531
5. T.S. Mok, Y.L. Wu, and S. Thongprasert Gefitinib or carboplatin- paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 2009 947 957
6. M. Soda, Y.L. Choi, and M. Enomoto Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer Nature 448 7153 2007 561 566 (Pubitemid 47206930)
7. L. Cote, T. John, and M.S. Tsao Molecular predictive and prognostic markers in non-small-cell lung cancer The Lancet Oncology 10 2009 1001 1010
8. G.R. Simon, S. Sharma, and A. Cantor ERCC1 Expression is predictive of survival in resected patients with non-small-cell lung cancer Chest 127 2005 978 983 (Pubitemid 40775532)
9. R. Lord, J. Brabender, and D. Gandara Low ERCC1 cxpression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small-cell lung cancer Clin Can Res 21 2002 2286 2291 (Pubitemid 34753602)
10. K.A. Olaussen, A. Dunant, and P. Fouret DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy N Engl J Med 355 2006 983 991 (Pubitemid 44343542)
11. B. Holm, A. Mellemgaard, and T. Skoy Different impact of cxcision repair cross-complementation group 1 on survival in male and female patients with inoperable non-small-cell lung cancer treated with carboplatin-gemcitabine J Clin Oncol 27 2009 4254 4259
12. M. Cobo, D. Isla, and B. Massuti Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer J Clin Oncol 25 2007 2747 2754 (Pubitemid 47123183)
13. Tailored post-surgical therapy in early stage NSCLC (TASTE) ClinicalTrials.gov [Web site] http://clinicaltrials.gov/show/NCT00775385 Accessed: October 12, 2010
14. G. Bepler, S. Sharma, and A. Cantor RRM1 and PTEN as prognostic parameters for overall survival and disease-free survival in patients with non-small-cell lung cancer J Clin Oncol 22 2004 1878 1885 (Pubitemid 41095179)
15. A. Gautam, Z.R. Li, and G. Bepler RRM1-induced metastasis suppression through PTEN-regulated pathways Oncogene 22 2003 2135 2142 (Pubitemid 36539563)
16. Z. Zheng, T. Chen, and X. Li DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer N Engl J Med 356 2007 800 808 (Pubitemid 46294612)
17. G. Bepler, I. Kustartseva, and S. Sharma RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer J Clin Oncol 24 2006 4731 4737 (Pubitemid 46646245)
18. R. Rosell, G. Scagliotti, and K.D. Danenberg Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer Oncogene 22 2003 3548 3553 (Pubitemid 36765314)
19. G. Simon, A. Sharma, and X. Li Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer J Clin Oncol 25 2007 2741 2746 (Pubitemid 47123182)
20. A. Bhattacharyya, U.S. Ear, and B.H. Koller The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin J Biol Chem 275 31 2000 23899 23903 (Pubitemid 30624678)
21. P. Tassone, P. Tagliaferri, and A. Perricelli BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells Br J Cancer 88 8 2003 1285 1291 (Pubitemid 36606348)
22. T. Suda, M. Nitta, and H. Saya Dependence of paclitaxel sensitivity on a functional spindle assembly checkpoint Cancer Res 64 7 2004 2502 2508 (Pubitemid 38523906)
23. S. Ota, G. Ishii, and K. Goto Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy Lung Cancer 64 2009 98 104
24. R. Bartolucci, J. Wei, and J.J. Sanchez XPG mRNA expression levels modulate prognosis in resected nonsmall-cell lung cancer in conjunction with BRCA1 and ERCC1 expression Clin Lung Cancer 10 1 2009 47 52
25. R. Rosell, M. Skrzypski, and E. Jassem BRCA1: A novel prognostic factor in resected non-small-cell lung cancer PLoS ONE 2 11 2007 e1129
26. M. Taron, R. Rosell, and E. Felip BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer Hum Mol Genet 13 20 2004 2443 2449 (Pubitemid 39377848)
27. L. Wang, J. Wei, and X. Qian ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel BMC Cancer 8 2008 97
28. C. Su, S. Zhou, and L. Zhang ERCC1, RRM1 and BRCA1 mRNA expression levels and clinical outcome of advanced non-small cell lung cancer Med Oncol May 14, 2010 10.1007/s12032-010-9553-9 [Epub ahead of print]
29. I. Buokovinas, C. Papadaki, and P. Mendez Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients PLoS One 3 11 2008 e3695 http://www.plosone.org/home.action Accessed: October 12, 2010
30. R. Rosell, L. Perez-Roca, and J.J. Sanchez Customized treatment in non-small cell lung cancer based on EGFR mutations and BRCA1 mRNA expression PLoS One 4 5 2009 e5133 10.1371/journal.pone.0005133 http://www.plosone.org/ home.action Accessed: October 12, 2010
31. P. Ceppi, M. Volante, and S. Saviozzi Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase Cancer 107 2006 1589 1596 (Pubitemid 44546920)
32. A.R. Hanauske, U. Eismann, and O. Oberschmidt In vitro chemosensitivity of freshly explanted tumor cells to pemetrexed is correlated with target gene expression Invest New Drugs 25 2007 417 423 (Pubitemid 47222911)
33. P. Peterson, K. Park, and F. Fossella Is pemetrexed more effective in adenocarcinoma and large cell lung cancer than in squamous cell carcinoma? A retrospective analysis of a phase III trial of pemetrexed vs docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC) J Thorac Oncol 2 suppl 4 2007 s316 s317
34. N. Hanna, F. Shepard, and F. Fossella Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy J Clin Oncol 22 2004 1589 1597 (Pubitemid 41079796)
35. G.V. Scaglotti, P. Parikh, and J. von Pawel Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-nave patients with advanced-stage non-small-cell lung cancer J Clin Oncol 26 2008 3543 3551
36. T. Ciuleanu, T. Brodowicz, and C. Zielinski Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study Lancet 374 2009 1432 1440
37. D.S. Salomon, R. Brandt, and F. Ciardiello Epidermal growth factor related peptides and their receptors in human malignancies Crit Rev Oncol Hematol 19 1995 183 232
38. F. Ciardiello, and G. Tortora EGFR antagonists in cancer treatment N Engl J Med 358 2008 1160 1174
39. R. Rosell, T. Moran, and C. Queralt Screening for epidermal growth factor receptor mutations in lung cancer N Engl J Med 361 2009 958 967
40. V. Rusch, D. Klimstra, and E. Venkatraman Overexpression of the epidermal growth factor and its ligand transforming growth factor alpha is frequent in resectable non-small-cell lung cancer but does not predict tumor progression Clin Cancer Res 3 1997 515 522 (Pubitemid 27211827)
41. F.R. Hirsch, M. Varella-Garcia, and P.A. Bunn Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis J Clin Oncol 21 2003 3798 3807 (Pubitemid 46606235)
42. F. Sheppard, J.R. Pereira, and T. Ciuleanu Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 353 2005 123 132 (Pubitemid 41058344)
43. N. Thatcher, A. Chang, and P. Parikh Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomized, placebo-controlled, multicenter study (Iressa Survival Evaluation in Lung Cancer) Lancet 366 2005 1527 1537 (Pubitemid 41540110)
44. G. Goss, D. Ferry, and R. Wiezerbicki Randomized phase II study of geftinib compared with placebo in chemotherapy nave patients with advanced non-small-cell lung cancer and poor performance status J Clin Oncol 27 2009 2253 2260
45. E. Kim, V. Hirsch, and T. Mok Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomized phase III trial Lancet 372 2008 1809 1818
46. L. Crino, F. Cappuzzo, and P. Zatloukal Gefitinib versus vinorelbine in chemotherapy-nave elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study J Clin Oncol 26 2008 4253 4260
47. W. Pao, V. Miller, and M. Zakowski EGF receptor gene mutations are common in lung cancer from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib Proc Natl Acad Sci USA 101 2004 13306 13311 (Pubitemid 39209661)
48. T.J. Lynch, D.W. Bell, and R. Sordella Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2004 2129 2139 (Pubitemid 38637993)
49. M. Maemondo, A. Inoue, and K. Kobayashi Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR N Engl J Med 362 2010 2380 2388
50. th European Society of Medical Oncology meeting, Milan, Italy October 8-12, 2010 (abstr LBA13)
51. W. Pao, V.A. Miller, and K.A. Politi Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain PLoS Med 2 3 2005 e73
52. S. Kobayashi, T.J. Boggon, and T. Dayaram EGFR mutation and resistance of non small cell lung cancer to gefitinib N Engl J Med 352 2005 786 792 (Pubitemid 40271173)
53. E.L. Kwak, R. Sordella, and D.W. Bell Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib Proc Natl Acad Sci USA 102 2005 7665 7670 (Pubitemid 40741028)
54. L.V. Sequist Second- generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer The Oncologist 12 2007 325 330 (Pubitemid 46556799)
55. J. Bean, C. Brennan, and J.Y. Shih MET amplification occurs with or without T790M mutation in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib Proc Natl Acad Sci USA 104 2007 20932 20937
56. J.A. Engelman, K. Zejnullahu, and T. Mitsudmi MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling Science 316 2007 1039 1043 (Pubitemid 46799492)
57. S. Rodenhius, M.L. van de Wetering, and W.J. Mooi Mutational activation of the K-ras oncogene: a possible pathogenetic factor in adenocarcinoma of the lung N Engl J Me 317 1987 929 935 (Pubitemid 17147935)
58. R.J. Slebos, R.H. Hruban, and O. Dalesio Relationship between K-ras oncogene activation and smoking in adenocarcinoma of the human lung J Natl Cancer Inst 83 1991 1024 1027
59. S. Sun, J.H. Schiller, and A.F. Gazdar Lung cancer in never smokers- a different disease Nat Rev Cancer 7 2007 778 790 (Pubitemid 47463669)
60. G.J. Riely, M.G. Kris, and D. Rosenbaum Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma Clin Cancer Res 14 18 2008 5731 5734
61. S.W. Han, T.Y. Kim, and Y.K. Jeon Optimization of patient selection for gefitinib in non-small cell lung cancer by combied analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation Clin Cancer Res 12 8 2006 2538 2544
62. S. Aviel-Ronen, F.H. Blackhall, and F.A. Shepherd K-ras mutations in non-small-cell lung carcinoma: a review Clin Lung Cancer 8 1 2006 30 38 (Pubitemid 44336241)
63. S.W. Morris, M.N. Kirstein, and M.B. Valentine Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma Science 263 5151 1994 1281 1284 (Pubitemid 24107549)
64. Y. Chen, J. Takita, and Y.L. Choi Oncogenic mutations of ALK kinase in neuroblastoma Nature 455 7215 2008 971 974
65. C.M. Coffin, J.L. Hornick, and C.D. Fletcher Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases Am J Surg Pathol 31 4 2007 509 520 (Pubitemid 46569034)
66. A.T. Shaw, B.Y. Yeap, and M. Mino-Kenudson Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK J Clin Oncol 27 26 2009 4247 4253
67. J.P. Koivunen, C. Mermel, and K. Zejnullahu EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer Clin Cancer Res 14 13 2008 4275 4283
68. K. Takeuchi, Y.L. Choi, and M. Soda Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts Clin Cancer Res 14 20 2008 6618 6624
69. S. Perner, P.L. Wagner, and F. Demichelis EML4-ALK fusion lung cancer: a rare acquired event Neoplasia 10 3 2008 298 302 (Pubitemid 351328588)
70. T. Takahashi, M. Sonobe, and M. Kobayashi Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene Ann Surg Oncol 17 3 2010 889 897
71. K. Inamura, K. Takeuchi, and Y. Togashi EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers J Thorac Oncol 3 1 2008 13 17
72. A.T. Shaw, B. Yeap, and D.B. Costa Prognostic versus predictive value of EML4-ALK translocation in metastatic non-small cell lung cancer J Clin Oncol 28 suppl 15 2010 564s (abstr 7606)
73. E.L. Kwak, D.R. Camidge, and J. Clark Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066 J Clin Oncol 27 suppl 15 2009 (abstr 3509) http://meeting.ascopubs.org/ Accessed October 12, 2010
74. E.L. Kwak, Y. Bang, and D.R. Camidge Anaplastic lymphoma kinase inhibition in non-small cell lung cancer N Eng J Med 363 18 2010 1693 1703
75. Phase 3, Randomized, Open-Label Study Of The Efficacy And Safety Of PF-02341066 Versus Standard Of Care Chemotherapy (Pemetrexed Or Docetaxel) In Patients With Non-Small Lung Cancer Harboring A Translocation Or Inversion Event Involving The Anaplastic Lymphoma Kinase (ALK) Gene Locus ClinicalTrials.gov [Web site] http://clinicaltrials.gov/ct2/results?term=+NCT00932893 Accessed: October 12, 2010
76. M. Kavallaris, C.A. Burkhart, and S.B. Horwitz Antisense oligonucleotides to class III beta-tubulin sensitize drug-resistant cells to taxol Br J Cancer 80 7 1999 1020 1025 (Pubitemid 29233923)
77. M. Hari, H. Yang, and C. Zeng Expression of class III beta-tubulin reduces microtubule assembly and confers resistance to paclitaxel Cell Motil Cytoskeleton 56 1 2003 45 56 (Pubitemid 37059485)
78. K. Kamath, L. Wilson, and F. Cabral BetaIII-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability J Biol Chem 280 13 2005 12902 12907
79. A. Musacchio, and E.D. Salmon The spindle-assembly checkpoint in space and time Nat Rev 8 5 2007 379 393 (Pubitemid 46643240)
80. P. Seve, J. Mackey, and S. Isaac Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel Mol Cancer Ther 4 12 2005 2001 2007 (Pubitemid 43056983)
81. C.H. Kang, B.G. Jang, and D.W. Kim The prognostic significance of ERCC1, BRCA1, XRCC1, and betaIII-tubulin expression in patients with non-small cell lung cancer treated by platinum- and taxane-based neoadjuvant chemotherapy and surgical resection Lung Cancer 68 3 2010 478 483
82. K. Azuma, T. Sasada, and A. Kawahara Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel Lung Cancer 64 3 2009 326 333
83. Y. Hayashi, H. Kuriyama, and H. Umezu Class III betatubulin expression in tumor cells is correlated with resistance to docetaxel in patients with completely resected non-small-cell lung cancer Intern Med 48 4 2009 203 208
84. P. Sve, and C. Dumontet Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents? Lancet Oncol 9 2 2008 168 175 (Pubitemid 351150128)